In brief
- A Gabonese presidential decree (No. 0239/PR, May 22, 2026) declares iboga a “strategic national asset,” moving its management beyond simple forestry regulations.
- From now on, researching, processing, exporting, or commercializing iboga in Gabon requires authorization from an interministerial technical commission.
- The decree creates a sovereign fund financed by licenses and royalties, as the price of iboga seedlings has quadrupled since the U.S. renewed its interest in ibogaine.
Gabon, the country where Tabernanthe iboga grows endemically, has decided to stop treating the plant as just another forestry product. A decree signed on May 22 and detailed in the following weeks by local media and the specialized publication Psychedelics Today reclassifies it as a strategic state resource, complete with its own sovereign fund and an administrative filter for anyone wishing to handle it, from pharmaceutical laboratories to university researchers.
From Forestry Raw Material to Sovereign Asset
Until this year, iboga was regulated by the Ministry of Water and Forests, like any other exportable plant species. The new decree transfers final authority to the Ministry of Culture, which must authorize access to the plant—as well as its research, processing, and commercialization—following approval from an interministerial technical commission created for this purpose. The text invokes the Nagoya Protocol and the mechanisms of the World Intellectual Property Organization to claim sovereignty over the resource and demand a “fair and equitable sharing of benefits” with the communities that guard the traditional knowledge, particularly those linked to the Bwiti religion, for which ibogaine has been a sacramental substance for generations.
Ibogaine Fever Drives Up Prices
The timing is no coincidence. In April, an executive order from the Trump Administration prioritized psychedelic research, and ibogaine in particular, for treating PTSD and depression, in parallel with major clinical programs already funded in Texas and Arizona. This push has sent international demand for Gabonese raw material soaring: according to Psychedelics Today, the price of iboga seedlings in the country rose from about $4 to about $17 in just a few months. Within Gabon, however, ibogaine remains classified as a Schedule I substance, meaning the country seeks to capture value from the foreign “boom” without opening the door to its own domestic consumption.
What This Implies
The measure responds to a real concern: the overexploitation of a slow-growing plant that is increasingly coveted by clinics and laboratories abroad, and the risk that this value will be extracted without leaving anything for the communities that have guarded it. Voices from within the Bwiti circle, cited in the reference report, warn that “a molecule extracted from its context is not the same medicine that our healers have practiced for generations” and are calling for community registries to document traditional knowledge before others patent it. For those following the clinical expansion of ibogaine outside of Africa, the underlying message is that the future availability of the plant, and likely its price, will depend increasingly on decisions made in Libreville rather than just Western bioethics committees. It is also a reminder that harm reduction regarding ibogaine involves knowing the origin and traceability of the bark being consumed, not just the dose.
Source
- Psychedelics Today. The Rush for Iboga Looks Different from Gabon. Psychedelics Today, July 13, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
